Affordable Access

Publisher Website

Chemotherapy in advanced bladder cancer: current status and future

Authors
Journal
Journal of Hematology & Oncology
1756-8722
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Volume
4
Issue
1
Identifiers
DOI: 10.1186/1756-8722-4-35
Keywords
  • Review
Disciplines
  • Biology
  • Medicine

Abstract

Bladder cancer occurs in the majority of cases in males. It represents the seventh most common cancer and the ninth most common cause of cancer deaths for men. Transitional cell carcinoma is the most predominant histological type. Bladder cancer is highly chemosensitive. In metastatic setting, chemotherapy based on cisplatin should be considered as standard treatment of choice for patients with good performance status (0-1) and good renal function-glomerular filtration rate (GFR) > 60 mL/min. The standard treatment is based on cisplatin chemotherapy regimens type MVAC, HD-MVAC, gemcitabine plus cisplatin (GC) or dose dense GC. In unfit patients, carboplatin based regimes; gemcitabine plus carboplatin or methotrexate plus carboplatin plus vinblastine (MCAVI) are reasonable options. The role of targeted therapies when used alone, or in combination with chemotherapy, or in maintenance, was evaluated; targeting angiogenesis seem to be very promising. The purpose of this literature review is to highlight the role of chemotherapy in the management of advanced transitional cell carcinoma of the bladder.

There are no comments yet on this publication. Be the first to share your thoughts.